Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)

NCT06291103 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

290

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant Rejection

Interventions

DRUG: Conversion to Belatacep
DRUG: Standard of care treatment (SOC regimen) with Tacrolimus

Sponsor

University Hospital, Rouen